{"filings":[{"id":93136,"accession_number":"0001193125-26-213439","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Operating expenses $9.9M, up 34% YoY; FDA grants RPD for (Z)-endoxifen in DMD and McCune-Albright","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total operating expenses $9.9M in Q1 2026, up from $7.4M in Q1 2025, driven by higher legal fees for patent litigation (subsequently settled) and R&D costs.","R&D expenses $4.8M (+15% YoY) on increased clinical trial costs for (Z)-endoxifen; G&A $5.1M (+56%) due to $1.8M in patent litigation legal fees.","FDA granted Orphan Drug Designation (Jan 2026) and Rare Pediatric Disease designation for (Z)-endoxifen in Duchenne Muscular Dystrophy.","FDA granted Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome (May 2026), eligible for Priority Review Voucher (sold for $100-205M).","Atossa strengthened leadership with two new Medical Directors: Dr. Puyana Theall (Breast Oncology) and Dr. Giwa (Rare Diseases)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93135,"accession_number":"0001193125-26-213373","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atossa shareholders approve reverse stock split up to 20:1, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved: 2,336,815 for, 1,866,873 against, 33,271 abstentions.","Three Class II directors re-elected: Galli, Steinhart, Cigler; broker non-votes ~2.2M each.","Ratification of Ernst & Young as auditor for FY 2026 passed: 3.7M for, 370K against, 151K abstentions.","Advisory vote on executive compensation approved: 1.53M for, 444K against, 2.22M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93134,"accession_number":"0001193125-26-158030","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atossa settles patent disputes with Intas; Endoxifen patents remain enforceable","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Entered Settlement Agreement on April 13, 2026 with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve Endoxifen patent disputes.","PTAB proceedings will be terminated; U.S. Patent Nos. 11,261,151 and 12,071,391 remain issued and enforceable.","Mutual covenants prevent parties from challenging each other's specified Endoxifen patents and applications.","Agreement preserves Atossa's ability to develop and commercialize Z-endoxifen base in oncology, endocrine disorders, and muscular dystrophy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104517,"accession_number":"0001193125-26-124393","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.","Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy.","Added Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. as Medical Directors for breast oncology and rare diseases.","Interest income decreased to $2.4M from $4.1M; no impairment charge in 2025 vs $1.7M in 2024.","(Z)-endoxifen being evaluated in multiple settings including breast cancer and rare diseases DMD and MAS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104516,"accession_number":"0001193125-26-061412","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Atossa enters $50M ATM equity offering with Rodman & Renshaw; terminates Jefferies facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM agreement allows up to $50M in common stock sales; company pays 3% commission to sales agent.","Proceeds intended for clinical development, working capital, and general corporate purposes.","Prior Jefferies ATM agreement terminated with no sales made; no termination penalties incurred.","Company not obligated to sell any shares; may suspend or terminate the arrangement at any time.","Offering registered under effective S-3 shelf (filed May 2024); prospectus supplement filed Feb 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104515,"accession_number":"0001193125-26-054797","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Atossa Therapeutics regains Nasdaq compliance on minimum bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Feb 17, 2026 confirming compliance with Listing Rule 5550(a)(2).","Had been non-compliant since Feb 21, 2025; deadline extended to Feb 17, 2026.","Met requirement by maintaining $1.00+ closing bid for 10 consecutive trading days through Feb 13, 2026.","Common stock will continue listed on The Nasdaq Capital Market without interruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104514,"accession_number":"0001193125-26-045628","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Atossa receives FDA Rare Pediatric and Orphan Drug designations for (Z)-endoxifen in DMD; pauses MBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Rare Pediatric Disease and Orphan Drug designations granted for (Z)-endoxifen in Duchenne Muscular Dystrophy (Dec 2025/Jan 2026).","Paused investment in metastatic breast cancer (MBC) to prioritize other oncology and rare disease programs.","Cash and equivalents >$40M as of early 2026, supporting >1 year of working capital.","Reverse stock split effective Feb 2, 2026 to regain Nasdaq listing compliance.","I-SPY 2 combination therapy enrollment near complete; preliminary data expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104513,"accession_number":"0001193125-26-021727","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Atossa shareholders approve 15:1 reverse stock split effective Feb 2, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved at Special Meeting: 33.7M for, 27.9M against, 0.1M abstentions; no broker non-votes.","Board set ratio at 15:1; effective 12:01 a.m. ET on Feb 2, 2026; trading begins on split-adjusted basis same day.","No fractional shares issued; cash paid in lieu based on Jan 30, 2026 closing price adjusted for split ratio.","Proportionate adjustments to outstanding equity awards, exercise prices, and Series B Preferred conversion price.","Par value remains $0.18 per share; CUSIP changes to 04962H704; ticker ATOS unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104512,"accession_number":"0001193125-26-008314","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Atossa reports preliminary cash balance of ~$40M, limited other details","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Estimated cash and cash equivalents of ~$40M as of Dec 31, 2025, preliminary and unaudited.","No quarterly earnings, revenue, or operational results were disclosed in this filing.","Updated corporate presentation likely focuses on (Z)-Endoxifen development strategy per forward-looking statements.","Cash estimate subject to finalization of year-end financial closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104511,"accession_number":"0001193125-26-003506","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atossa Therapeutics receives FDA 'Study May Proceed' letter for (Z)-Endoxifen metastatic breast cancer trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA issued 'Study May Proceed' letter for Atossa's IND for (Z)-Endoxifen in metastatic ER+/HER2- breast cancer.","Trial will evaluate (Z)-Endoxifen in tumors resistant to other endocrine therapies; targets PKCβ1 pathway.","CEO Dr. Steven Quay calls this an important regulatory milestone to expand (Z)-Endoxifen's potential use.","(Z)-Endoxifen is a potent SERM/D with distinct pharmacology from tamoxifen; not yet approved for any indication.","Program backed by growing global IP portfolio including issued U.S. patents and pending applications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120802,"accession_number":"0001193125-25-307516","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atossa completes FDA Type C meeting; gains clarity on accelerated (Z)-endoxifen development","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA provided feedback on regulatory pathways for (Z)-endoxifen across metastatic, neoadjuvant, and risk-reduction settings.","Company submitted IND for metastatic breast cancer program and awaits FDA feedback.","Phase 2 EVANGELINE trial continuing in neoadjuvant ER+/HER2- breast cancer.","Nearly 800 participants in completed trials; no MTD identified up to 360 mg/day.","Additional IND submissions planned in 2026 for combination strategies beyond monotherapy and breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120801,"accession_number":"0001193125-25-276140","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa advances (Z)-endoxifen regulatory path; Q3 op-ex $9.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA Type C meeting set Nov 17 to discuss accelerated NDA path for (Z)-endoxifen in breast cancer risk reduction; written comments received.","Appointed Janet R. Rea as SVP R&D and Mark Daniel as CFO to lead commercialization readiness.","Selected PSI as CRO for planned Phase 2 mBC dose-ranging study; IND filing targeted Q4 2025, topline data in 2026.","Q3 operating expenses $9.3M (up from $6.4M); interest income $0.6M; net loss not separately disclosed.","New Israel patent issued; two US patents under post-grant challenges; majority of IP portfolio unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120800,"accession_number":"0001193125-25-238065","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Atossa appoints Mark Daniel as CFO to lead finance for commercial readiness","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Daniel appointed CFO effective Oct 14; Heather Rees transitions to non-officer employee through Nov 15.","Daniel receives $415,900 base salary, 40% target bonus, and 578,000-share stock option grant vesting over 4 years.","Daniel brings 25+ years life-science finance; previously SVP Finance at Bruker Spatial Biology until 2025.","He has managed $400M cash portfolio and executed ~$1B in equity/debt transactions, supporting Atossa's commercial launch of (Z)-endoxifen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137402,"accession_number":"0001193125-25-220788","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Atossa Therapeutics posts updated corporate presentation; no specific financial details provided","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed as Exhibit 99.1 on September 26, 2025, but presentation content not included in this filing text.","No new financial figures, pipeline milestones, or guidance changes are extractable from the available text.","Ticker ATOS; company is a clinical-stage biotech focused on breast cancer treatments.","Investors would need to view the actual presentation to assess any material updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137401,"accession_number":"0000950170-25-113371","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atossa requests FDA Type C meeting to accelerate low-dose (Z)-endoxifen for breast cancer risk reduction","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company requested a Type C FDA meeting; expects update by year-end 2025.","Favorable outcome could shorten approval timeline by years and avoid tens of millions in trial costs.","Cash position of $57.9M with no debt as of June 30, 2025; potential multi-billion-dollar market highlighted.","Annual U.S. tamoxifen prescriptions estimated at 1.6-2.1 million; 4.3M women live with breast cancer history.","(Z)-endoxifen avoids CYP2D6 metabolism issues affecting ~20% of tamoxifen patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137400,"accession_number":"0000950170-25-110654","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Atossa Therapeutics receives Nasdaq extension to Feb 17, 2026 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Atossa on Feb 21, 2025 of non-compliance with $1.00 min bid price rule.","Initial compliance period ended Aug 20, 2025; extension granted to Feb 17, 2026.","Company may consider a reverse stock split to regain compliance.","No immediate impact on Nasdaq listing or trading of ATOS shares.","Atossa is monitoring bid price and evaluating available options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137399,"accession_number":"0000950170-25-106944","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa Q2 operating expenses $9M; FDA clears IND path for (Z)-endoxifen in metastatic breast cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total operating expenses $9.0M in Q2 2025, up 27% YoY from $7.1M; R&D spend rose 55% to $5.5M.","FDA feedback July 2025: no additional toxicity studies needed; Atossa plans IND submission in Q4 2025 for (Z)-endoxifen in metastatic breast cancer.","I-SPY2 pilot (20 patients): 95% completed ≥75% dosing; median Ki-67 dropped from 10.5% to 5%; functional tumor volume decreased 77.7% by MRI.","Issued U.S. Patent 12,281,056 with 58 claims covering (Z)-endoxifen enteric formulations; two other patents under post-grant challenge."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154711,"accession_number":"0000950170-25-069818","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa Q1 cash $65.1M; pivots (Z)-endoxifen to metastatic breast cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ended Q1 2025 with $65.1M cash, no debt; no revenue reported.","Strategic shift to metastatic breast cancer as lead indication for (Z)-endoxifen.","Added 3 new US patents, expanding IP portfolio to over 200 claims related to (Z)-endoxifen.","Operating expenses $7.4M (up $0.4M YoY) with R&D $4.2M, G&A $3.3M.","Interest income $0.7M, down from $1.1M due to lower money market balance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154710,"accession_number":"0000950170-25-068333","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Atossa stockholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors Steven C. Quay (28.4M for, 4.2M withheld) and Jonathan F. Finn (30.2M for, 2.4M withheld) elected.","Ratification of Ernst & Young as auditor passed with 55.8M for, 6.7M against, 1.4M abstain.","Non-binding advisory vote on executive compensation approved with 25.6M for, 6.5M against, 0.5M abstain.","Stockholders selected one-year frequency for future say-on-pay votes (29.3M votes for 1 year).","Record date March 20, 2025; 129,170,004 shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154709,"accession_number":"0000950170-25-051575","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Intas Pharmaceuticals challenges two Atossa endoxifen patents with PGR and IPR petitions at USPTO","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Intas filed PGR petition against U.S. Patent No. 12,071,391, titled 'Methods for Making and Using Endoxifen'.","Intas also filed IPR petition against U.S. Patent No. 11,261,151, also titled 'Methods for Making and Using Endoxifen'.","Atossa intends to vigorously contest the petitions and believes the patents are valid and enforceable.","No assurance that Atossa will prevail in the USPTO proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173235,"accession_number":"0000950170-25-044098","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa Therapeutics ends 2024 with $71.1M cash; advances (Z)-endoxifen for metastatic breast cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $71.1M, no debt; operating expenses fell to $27.6M from $31.4M in 2023.","Strategic pivot to pursue metastatic breast cancer indication for (Z)-endoxifen, citing streamlined regulatory path.","Phase 2 EVANGELINE trial of (Z)-endoxifen showed Ki-67 ≤10% response rate >85% across doses; amended protocol to compare 40mg + OFS vs exemestane + OFS.","Phase 2 KARISMA-Endoxifen: 1mg and 2mg doses reduced mammographic breast density by 17.3 and 23.5 percentage points (p<0.01) vs placebo 0.27 pts.","R&D expenses down 19% to $14.1M; G&A expenses down 4% to $13.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173234,"accession_number":"0000950170-25-037634","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atossa to pursue metastatic breast cancer indication; (Z)-endoxifen more than doubled PFS vs tamoxifen (7.2 vs 2.4 mo)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic decision to pursue metastatic breast cancer indication for (Z)-endoxifen, citing potentially faster regulatory path.","Median PFS more than doubled to 7.2 months vs 2.4 months for tamoxifen in CDK4/6i-naïve patients.","Also engaging FDA on additional indications: breast cancer prevention and neoadjuvant therapy.","Early data show Ki-67 ≤10% response rate above 85% across doses in neoadjuvant setting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173233,"accession_number":"0000950170-25-025596","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Atossa receives Nasdaq minimum bid price deficiency notice; compliance period through Aug 20, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Feb 21, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days.","Compliance period ends Aug 20, 2025; possible additional 180-day extension if not compliant by then.","To regain compliance, common stock must close at $1.00+ for at least 10 consecutive business days.","Notice has no immediate effect on stock listing or trading; company monitoring and evaluating options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173232,"accession_number":"0000950170-25-012868","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PTAB invalidates Atossa's US Patent 11,572,334; new patent 12,201,591 issued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PTAB final decision found all claims of US Patent 11,572,334 unpatentable; Atossa will not appeal.","Atossa issued new US Patent 12,201,591 (Sustained Release Compositions of Endoxifen) with 31 claims.","Company states decision has no impact on current clinical formulations; will pursue continuation patent application.","Patent estate now includes four issued US patents covering formulations in development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190253,"accession_number":"0000950170-24-134779","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Atossa presents positive PK/tolerability data from Phase 2 EVANGELINE trial of (Z)-endoxifen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["50% of patients on 80 mg (Z)-endoxifen + goserelin met target plasma Css of 500-1,000 ng/mL.","Tissue Css levels >2x plasma; >90% of patients achieved target tissue levels >500 ng/g.","Ki-67 ≤10% response rate >85% across doses after 4 weeks, indicating antitumor activity.","(Z)-endoxifen well tolerated with no Grade 3-4 toxicities; four gynecologic events in 80 mg groups.","Randomized trial to compare 40 mg + OFS vs exemestane + OFS; recruitment expected to start 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190252,"accession_number":"0000950170-24-128686","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Atossa Therapeutics enters at-the-market equity facility for up to $100M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies LLC dated Nov 19, 2024 to sell up to $100M of common stock at-the-market.","Commission to Jefferies is up to 3.0% of gross proceeds; company reimburses certain expenses.","Proceeds intended for clinical development, working capital, and general corporate purposes.","No obligation to sell any shares; company may suspend or terminate the agreement at any time.","Shares registered under effective S-3 filed May 13, 2024; prospectus supplement filed Nov 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190251,"accession_number":"0000950170-24-124655","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa Therapeutics reports Q3 2024 results, highlights positive Phase 2 data for (Z)-endoxifen","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Announced positive topline from KARISMA-Endoxifen Phase 2: MBD reductions of 19.3% (1 mg) and 26.5% (2 mg) vs placebo.","Preliminary I-SPY 2 EOP analysis: 95% (19/20) of patients met primary endpoint with >75% treatment completion.","First patient dosed in combination trial of (Z)-endoxifen with abemaciclib (VERZENIO) in ER+/HER2- breast cancer.","Ended Q3 2024 with $74.8 million cash and equivalents, no debt.","Received new U.S. Patent No. 12,071,391 covering (Z)-endoxifen compositions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190250,"accession_number":"0000950170-24-120268","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Atossa reports positive Phase 2 data for (Z)-endoxifen reducing breast density by up to 26.5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Relative MBD reduction of 19.3% (1 mg) and 26.5% (2 mg) vs placebo in KARISMA-Endoxifen trial.","Mean plasma endoxifen: 5.18 ng/mL (1 mg) and 10.87 ng/mL (2 mg) after 1 month; stable at 3 and 6 months.","Drug-related discontinuations: 4 placebo, 5 (1 mg), 12 (2 mg); vasomotor symptoms minimal on 10-point scale.","Historical tamoxifen study: 10%+ density reduction associates with 62% lower 5-year breast cancer incidence.","Detailed results to be presented at San Antonio Breast Cancer Symposium in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206753,"accession_number":"0000950170-24-095097","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa reports $79.5M cash, no debt; EVANGELINE Phase 2 40mg cohort shows 100% disease control rate","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended Q2 2024 with $79.5M cash and cash equivalents, no debt; interest income $1.1M in Q2.","Total operating expenses $7.1M in Q2 2024 vs $7.8M in Q2 2023, down 9% YoY.","Phase 2 EVANGELINE 40mg cohort achieved 100% disease control rate at 24 weeks for ER+/HER2- breast cancer.","Completed enrollment in EVANGELINE 80mg PK run-in cohort and dosing in Phase 2 Karisma-Endoxifen trial (240 patients).","Appointed Heather Rees as CFO; joined Russell 3000 Index effective June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206752,"accession_number":"0000950170-24-080497","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Atossa appoints Heather Rees as CFO, increases authorized shares to 360M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Rees appointed CFO effective June 27, 2024; salary set at $439,700 with 40% bonus target.","Rees granted 577,700 stock options vesting quarterly over two years under the 2020 Plan.","Stockholders approved increase in authorized common shares from 175M to 350M (total authorized to 360M).","Amendment and restatement of 2020 Stock Incentive Plan approved, adding 12M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223980,"accession_number":"0000950170-24-058242","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa Q1 2024 net loss $5.9M; EVANGELINE 100% disease control at 24 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.9M (operating expenses $7.0M, interest income $1.1M); cash $84.0M, no debt.","EVANGELINE study: 100% disease control rate, 37% avg lesion size reduction, 92% Ki-67 drop at 24 weeks.","Initiated combination study of (Z)-endoxifen + abemaciclib in ER+/HER2- breast cancer (20 patients).","I-SPY 2 Phase 2 trial fully enrolled; data readout expected in H2 2024.","Appointed medical oncologist Dr. Tessa Cigler to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223978,"accession_number":"0000950170-24-039634","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K/A","filed_at":"2024-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa reports FY2023 results: $88.5M cash, R&D spend up; two Phase 2 trials fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended FY2023 with $88.5M cash and equivalents, no debt.","Total operating expenses were $31.4M, up from $27.7M in FY2022, driven by higher R&D and G&A.","Two Phase 2 trials fully enrolled (Karisma-Endoxifen and I-SPY2); top-line data awaited H2 2024.","Recorded $3.0M impairment charge on investment in DCT; interest income rose to $4.3M from $0.9M.","Data from EVANGELINE Phase 2 study to be presented at AACR Annual Meeting on April 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223979,"accession_number":"0000950170-24-039286","cik":1488039,"company_name":"ATOSSA THERAPEUTICS, INC.","ticker":"ATOS","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Atossa ends FY2023 with $88.5M cash; two Phase 2 studies fully enrolled, data due H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $88.5M as of Dec 31, 2023; no debt outstanding.","Operating expenses $31.4M in 2023, up $3.7M from $27.7M in 2022.","Phase 2 Karisma-Endoxifen (breast density) fully enrolled Nov 2023; top-line data expected H2 2024.","Phase 2 I-SPY 2 (neoadjuvant breast cancer) fully enrolled Feb 2024; data expected H2 2024.","First patient dosed in Phase 2 RECAST DCIS study; EVANGELINE data at AACR April 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":43676824.65625,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}